PHAXIAM Therapeutics S.A. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-12-02: Study NCT04292743; Company role Collaborator; Phase Phase 1; Status Completed.
- 2019-06-13: Study NCT03674242; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Terminated.
- 2018-09-15: Study NCT03665441; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2017-08-23: Study NCT03267030; Company role Collaborator; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-12-02 | NCT04292743 Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma | Collaborator Lead: Georgetown University | Phase 1 | Completed Results posted | Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma | 19 | 2024-03-04 |
| 2019-06-13 | NCT03674242 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) | Lead sponsor | Phase 2, Phase 3 | Terminated | Triple Negative Breast Cancer | 27 | 2022-03-31 |
| 2018-09-15 | NCT03665441 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC | Lead sponsor | Phase 3 | Completed Results posted | Pancreatic Adenocarcinoma | 512 | 2022-01-18 |
| 2017-08-23 | NCT03267030 Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | Collaborator Lead: Birgitte Klug Albertsen | Phase 2 | Completed Results posted | Acute Lymphoblastic Leukemia | 55 | 2020-10-22 |
| 2014-07 | NCT02195180 Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma | Lead sponsor | Phase 2 | Completed | Pancreatic Adenocarcinoma Metastatic | 141 | 2017-11 |
| 2013-10 | NCT01910428 L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL | Lead sponsor | Phase 1 | Terminated | Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma | 14 | 2018-03 |
| 2013-02 | NCT01810705 GRASPA Treatment for Patients With Acute Myeloblastic Leukemia | Lead sponsor | Phase 2 | Completed Results posted | Acute Myeloid Leukemia | 123 | 2017-11-10 |
| 2009-12 | NCT01518517 GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Acute Lymphoblastic Leukemia, in Relapse | 85 | 2016-10 |
| 2009-11 | NCT01523808 Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer | Lead sponsor | Phase 1 | Completed Results posted | Pancreatic Cancer | 12 | 2011-03 |
| 2009-04 | NCT01523782 Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia | Lead sponsor | Phase 2 | Completed Results posted | Acute Lymphoblastic Leukemia | 30 | 2012-10 |
| 2006-01 | NCT00723346 Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia | Lead sponsor | Phase 1, Phase 2 | Completed | Acute Lymphoblastic Leukemia | 25 | 2009-03 |
| NCT02197650 Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase | Lead sponsor | Expanded_access | No longer available | Acute Lymphoblastic Leukemia |